BioStock: WntResearch’s Foxy-5 shows potential in leukemia

In parallel with the ongoing phase II study in colon cancer, WntResearch is also evaluating other potential target indications for the drug candidate Foxy-5. In collaboration with a Brazilian team of researchers, acute myeloid leukemia is now being identified as a possible indication, resulting in a patent application being filed. BioStock contacted CEO Anders Rabbe to find out more about what this means for the company.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/01/wntresearchs-foxy-5-shows-potential-in-leukemia/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se